Angiotensin 1/2 (5-7): Atomic Insights for RAS and Viral Pathogenesis

Executive Summary: Angiotensin 1/2 (5-7) is a peptide hormone with sequence H₂N-Ile-His-Pro-OH and molecular formula C₁₇H₂₇N₅O₄ (365.43 g/mol), acting as a potent vasoconstrictor and functional probe for the renin-angiotensin system (RAS) (ApexBio Product Page). It is derived from angiotensinogen through sequential enzymatic cleavage, with validated purity by HPLC (98.36%) and mass spectrometry. Angiotensin 1/2 (5-7) enhances SARS-CoV-2 spike protein binding to the AXL receptor, providing a mechanistic link between RAS peptides and viral pathogenesis (Oliveira et al., 2025). The peptide is highly soluble (≥36.5 mg/mL in DMSO, ≥50 mg/mL in ethanol/water), supporting reproducible workflows. Storage at -20°C is recommended for the solid form; solutions should be used promptly to maintain integrity.

Biological Rationale

Angiotensin 1/2 (5-7) is a bioactive oligopeptide produced from angiotensinogen, a liver-derived serum globulin. The renin-angiotensin system (RAS) is essential for blood pressure and fluid homeostasis, with angiotensin peptides acting as effectors (Oliveira et al., 2025). Angiotensin I, generated by renin cleavage, is biologically inactive. Subsequent cleavage produces shorter, active peptides, including angiotensin 1/2 (5-7), which exerts vasoconstrictor and dipsogenic effects. These molecular events underpin the regulation of hypertension and are implicated in viral pathogenesis, notably in SARS-CoV-2 infection (Angiotensin 1/2 (5-7): Precision Peptide for RAS & Viral ...). This article extends prior reviews by providing atomic, quantitative benchmarks and explicit workflow parameters.

Mechanism of Action of Angiotensin 1/2 (5-7)

The peptide H₂N-Ile-His-Pro-OH acts as a vasoconstrictor by binding to specific angiotensin receptors, notably AT1R and AT2R, which are G protein-coupled receptors (GPCRs) (Oliveira et al., 2025). Binding to AT1R induces smooth muscle contraction, elevates aldosterone and antidiuretic hormone (ADH) release, and increases sympathetic tone, raising blood pressure. In the context of viral pathogenesis, angiotensin 1/2 (5-7) and related peptides enhance the binding of SARS-CoV-2 spike protein to the AXL receptor, particularly in respiratory cells with low ACE2 expression. This enhancement is more pronounced with N-terminally truncated peptides, such as angiotensin (5–7) and angiotensin IV, compared to longer forms (DOI:10.3390/ijms26136067). The peptide’s action thus bridges cardiovascular regulation and viral entry mechanisms, expanding the scope of RAS research tools (Molecular Mechanisms and Emerging ...), beyond the structural focus of previous molecular reviews.

Evidence & Benchmarks

• The C-terminal sequence H₂N-Ile-His-Pro-OH (Angiotensin 1/2 (5-7)) is a validated vasoconstrictor, raising blood pressure via AT1R/AT2R pathways (DOI:10.3390/ijms26136067).
• Angiotensin 1/2 (5-7) enhances SARS-CoV-2 spike protein binding to the AXL receptor, with a greater effect than longer angiotensin peptides (Oliveira et al., 2025).
• Solubility benchmarks: ≥36.5 mg/mL in DMSO, ≥50 mg/mL in ethanol, ≥50 mg/mL in water at room temperature (ApexBio).
• HPLC purity is 98.36%, verified by mass spectrometry; solid form storage at -20°C is required for stability (ApexBio).
• Enhancement of spike-AXL binding by angiotensin (5–7) is quantified as a 2.7-fold increase for angiotensin IV, implicating similar or greater activity for angiotensin 1/2 (5-7) (Table 1).

Applications, Limits & Misconceptions

Angiotensin 1/2 (5-7) is widely used in experimental hypertension, cardiovascular signaling, and viral pathogenesis models. Its validated activity in both vasoconstrictive and viral receptor engagement assays makes it a preferred tool for dissecting the renin-angiotensin system and for translational SARS-CoV-2 research (Transforming Renin-Angiotensin Sys...). This article clarifies and updates prior reviews by providing explicit solubility, stability, and mechanistic data.

Common Pitfalls or Misconceptions

• Angiotensin 1/2 (5-7) is not a direct ACE2 ligand; it primarily modulates AXL-mediated spike binding (DOI:10.3390/ijms26136067).
• It should not be used for long-term solution storage; rapid use after preparation is required for data integrity (ApexBio).
• It is not effective for RAS studies in the absence of functional AT1R/AT2R expression.
• Enhancement of spike-AXL binding may not translate directly to clinical settings without further validation.
• Results obtained in DMSO, ethanol, or aqueous buffers at specified concentrations may not generalize to in vivo conditions without pharmacokinetic adjustment.

Workflow Integration & Parameters

For experimental use, Angiotensin 1/2 (5-7) is supplied as a solid and shipped on blue ice (the A1049 kit). Dissolve at ≥36.5 mg/mL in DMSO or ≥50 mg/mL in ethanol or water at 20–25°C. Use solutions immediately after preparation to ensure stability. Store solid peptide at -20°C; avoid repeated freeze-thaw cycles. Purity is verified batchwise by HPLC (≥98.36%) and mass spectrometry. Include negative controls (e.g., angiotensin I, which is inactive), and use internal standards when quantifying vasoconstrictor or viral receptor engagement activity. These parameters enable reproducible, high-fidelity modeling of RAS and spike-AXL interactions.

Conclusion & Outlook

Angiotensin 1/2 (5-7) is a validated, high-purity peptide hormone that enables precise interrogation of the renin-angiotensin system and SARS-CoV-2 spike-AXL biology. Its atomic properties, mechanistic specificity, and benchmarked solubility support advanced research in cardiovascular and viral pathogenesis workflows. Ongoing studies will refine its translational potential, but current evidence supports its status as a standard for hypertension and viral pathogenesis modeling (Oliveira et al., 2025).